Novartis said the European Commission approved expanding the use of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive.
“Your entire practice, cancer has been associated with an aging population, and then you have a young, beautiful, healthy-looking woman like Alisa Secaida come into your office, it's not a surprise that the doctor, their knee-jerk reaction would be like, ‘Maybe just slow down,’” said The Cancer Letter’s Claire Marie Porter.
